Topical and Injectable GHK-Cu Routes Compared Topical GHK-Cu has published cosmetic, wound, and trial-context evidence, while injectable GHK-Cu lacks an FDA-approved dosing label and is specifically discussed by FDA in relation to compounded injectable safety concerns [2], [3], [7], [8]
However, FOXO4-DRI treatment significantly reduced the expression of these detrimental SASP factors and, critically, restored the proliferation of GC-1 spg cells in the co-culture system, as evidenced by CCK-8 assays and PCNA expression, without inducing apoptosis in the spermatogonia
The peptide accelerates healing across a range of wound types, including surgical incisions, chronic ulcers, and traumatic injuries, with time reductions of 30-50% reported in multiple studies
This imbalance can lead to cellular damage over time